Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis.

Richardson-Harman N, Lackman-Smith C, Fletcher PS, Anton PA, Bremer JW, Dezzutti CS, Elliott J, Grivel JC, Guenthner P, Gupta P, Jones M, Lurain NS, Margolis LB, Mohan S, Ratner D, Reichelderfer P, Roberts P, Shattock RJ, Cummins JE Jr.

J Clin Microbiol. 2009 Nov;47(11):3530-9. doi: 10.1128/JCM.00673-09. Epub 2009 Sep 2.

2.

Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.

Richardson-Harman N, Mauck C, McGowan I, Anton P.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1422-33. doi: 10.1089/AID.2012.0073. Epub 2012 Sep 20.

3.

In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.

Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, Buckheit RW Jr, Watson K, Dezzutti CS, Cummins JE, Bromley E, Richardson-Harman N, Pallansch LA, Lackman-Smith C, Osterling C, Mankowski M, Miller SR, Catalone BJ, Welsh PA, Howett MK, Wigdahl B, Turpin JA, Reichelderfer P.

Antimicrob Agents Chemother. 2006 Feb;50(2):713-23.

4.

Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.

Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, de Bethune MP, Nuttall J, Romano J, Shattock R.

Antimicrob Agents Chemother. 2009 Feb;53(2):487-95. doi: 10.1128/AAC.01156-08. Epub 2008 Nov 24.

5.

Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.

Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ.

J Gen Virol. 2009 Jan;90(Pt 1):234-43. doi: 10.1099/vir.0.004358-0.

PMID:
19088294
6.

Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants.

Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ.

AIDS. 2011 Oct 23;25(16):1971-9. doi: 10.1097/QAD.0b013e32834b3629.

PMID:
21811139
7.

Clinical development of microbicides for the prevention of HIV infection.

D'Cruz OJ, Uckun FM.

Curr Pharm Des. 2004;10(3):315-36. Review.

PMID:
14754390
8.

Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.

Cummins JE Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA, Paxton L, Dezzutti CS.

Antimicrob Agents Chemother. 2007 May;51(5):1770-9. Epub 2007 Mar 12.

9.

Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.

Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ.

Retrovirology. 2006 Aug 1;3:46.

10.

Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model.

Mesquita PM, Wilson SS, Manlow P, Fischetti L, Keller MJ, Herold BC, Shattock RJ.

J Virol. 2008 Jul;82(13):6576-84. doi: 10.1128/JVI.00335-08. Epub 2008 Apr 23.

11.

Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay.

Watson KM, Buckheit CE, Buckheit RW Jr.

Antimicrob Agents Chemother. 2008 Aug;52(8):2787-96. doi: 10.1128/AAC.01657-07. Epub 2008 Jun 16.

12.

A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection.

Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE Jr, Fink A, Gilmore GT, Staley C, Ward A, Ali O, Binderow S, Cohen S, Grohskopf LA, Paxton L, Hart CE, Dezzutti CS.

J Infect Dis. 2005 Nov 1;192(9):1545-56. Epub 2005 Sep 26.

13.

Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides.

Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ.

AIDS. 2006 Jun 12;20(9):1237-45.

PMID:
16816551
14.

Study of HIV-1 transmission across cervical mucosa to tonsil tissue cells using an organ culture.

Soto-Rivera J, Patterson BK, Chen Y, Shen C, Ratner D, Ding M, Tumne A, Gupta P.

Am J Reprod Immunol. 2013 Jan;69(1):52-63. doi: 10.1111/aji.12018. Epub 2012 Oct 18.

PMID:
23078199
15.

Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.

Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ.

J Virol. 2000 Jun;74(12):5577-86.

16.

Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.

Gupta P, Ratner D, Ding M, Patterson B, Rohan LC, Reinhart TA, Ayyavoo V, Huang X, Patton DL, Ramratnam B, Cole AM.

J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):455-61.

17.

Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studies.

McGowan I, Tanner K, Elliott J, Ibarrondo J, Khanukhova E, McDonald C, Saunders T, Zhou Y, Anton PA.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1509-12. doi: 10.1089/AID.2012.0062. Epub 2012 Sep 4.

18.

Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety.

Cummins JE Jr, Doncel GF.

Sex Transm Dis. 2009 Mar;36(3 Suppl):S84-91. doi: 10.1097/OLQ.0b013e3181994191. Review.

PMID:
19218890
20.

Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Fraietta JA, Mueller YM, Do DH, Holmes VM, Howett MK, Lewis MG, Boesteanu AC, Alkan SS, Katsikis PD.

Antimicrob Agents Chemother. 2010 Oct;54(10):4064-73. doi: 10.1128/AAC.00367-10. Epub 2010 Jul 12.

Items per page

Supplemental Content

Write to the Help Desk